“Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis”, J of Skin, vol. 7, no. 2, p. s154, Mar. 2023, doi: 10.25251/skin.7.supp.154.